On Dec. 14, 2020, Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafiﾮ), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet its primary endpoint.

Initial data showed that there was no reduction in the proportion of patients receiving ruxolitinib plus SoC who experienced severe complications including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit (ICU) care by Day 29, compared to SoC treatment alone.